Comparative Pharmacology
Head-to-head clinical analysis: DYNAPEN versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNAPEN versus PYOPEN.
DYNAPEN vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
4 g intravenously every 4 hours.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic